...
机译:Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial (VOL 401, PG 105, 2023)
Fac Publ Hlth & Policy,London Sch Hyg Trop Med;
World Org Family Doctors;
National University of Singapore,Natl Univ Singapore;